Immutep (NASDAQ:IMMP) Stock Crosses Above 50-Day Moving Average – What’s Next?

Shares of Immutep Limited (NASDAQ:IMMP) crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $1.99 and traded as high as $2.05. Immutep shares last traded at $1.95, with a volume of 104,357 shares trading hands.

Wall Street Analyst Weigh In

Separately, Robert W. Baird raised their price objective on shares of Immutep from $6.00 to $7.00 and gave the company an “outperform” rating in a research note on Friday, November 15th.

Immutep Stock Down 1.5 %

The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.25 and a current ratio of 18.25. The business’s 50-day moving average price is $1.99 and its 200-day moving average price is $2.16.

Institutional Trading of Immutep

Several institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd purchased a new stake in shares of Immutep during the second quarter worth about $26,000. XY Capital Ltd purchased a new stake in Immutep during the 2nd quarter valued at approximately $105,000. Finally, Meridian Wealth Management LLC raised its position in shares of Immutep by 4.5% during the third quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company’s stock valued at $881,000 after buying an additional 17,250 shares during the last quarter. 2.32% of the stock is currently owned by institutional investors.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.